BIONOTE Webinar on "Cat Inflammation Diagnosis and Biomarker" was successfully held on June 2nd with nearly 600 veterinarians present. Dr. Yoo, director of Dr. Cat animal hospital, appeared as a speaker. Dr. Yoo emphasized the need for SAA tests for inflammatory screening purposes in cats visiting the hospital with non-specific clinical symptoms such as loss of appetite, weight loss, and depression. SAA (Serum amyloid A) is one of the acute phase proteins (APPs) secreted by the liver by inflammatory stimulation and is a useful inflammatory indicator in cats. When there are inflammatory stimuli such as tissue injury, infection, and muscle breakdown, monocytes and macrophages are activated, causing the secretion of cytokines such as IL-6. This stimulates the liver to release several APPs such as CRP, SAA, and Haptoglobin, causing systemic inflammatory reactions, including leukocytosis. Since the secretion of APPs precedes the increase in white blood cells, an increase in SAA levels can be observed earlier than the WBC levels in inflammatory situations. SAA begins to increase within 3 hours of inflammatory stimulation, reaching its peak after 48-72 hours. This biomarker increases in situations such as acute and chronic inflammation, infection, necrosis, injury, and malignant tumors. Therefore, SAA is widely understood as a marker capable of initial diagnosis of inflammation or infection, and is considered a basic test item in cats with clinical symptoms. It can also be used for monitoring purposes in cats before and after surgery. A good prognosis can be expected if SAA levels reach their peak 2-3 days after surgery and return to normal within 7 days, but if high SAA levels continue to be maintained, it suggests that there is postoperative infection. However, in the case of liver disease, careful interpretation is required with other diagnostic tools, because SAA levels may be low even in inflammatory situations because APPs are not sufficiently produced. Finally, Dr. Yoo provided easy guidance to the clinical usability through several real-case introductions using SAA in various diseases such as chronic rhinosinusitis, viral infection (herpesvirus, calicivirus), and feline infectious peritonitis (FIP). BIONOTE released the Vcheck Feline SAA 3.0 kit last year. Vcheck Feline SAA is a biomarker for inflammation diagnosis and monitoring in cats (Learn more). This kit can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (5 minutes) and can be tested using a small amount of sample (serum, plasma 5 µl). If you are interested in Vcheck Feline SAA 3.0, please contact your local distributor or send your request to [firstname.lastname@example.org].
SDB Investment is donating KRW 25 billion(₩) to Seoul National University. Seoul National University held a signing ceremony for Bionote, Inc., in the presence of key figures from the school including President Se-Jeong Oh, Vice President of Planning Won-Woo Lee, Dean of Veterinary Medicine Ho-Jae Han, and many others. A plaque of appreciation has also been delivered to SD Biosensor/Bionote Chairman Cho Young-Sik. After graduating from Seoul National University's College of Veterinary Medicine in 1984, Cho joined Green Cross, a pharmaceutical company. There, he was in charge of developing diagnostic reagent and product production for 13 years, and also served as a manager for domestic and overseas marketing division. During his career, he graduated from Seoul National University College of Veterinary Medicine with Master's and Doctorate degrees in veterinary biochemistry to further improve his professional capabilities. As the current chairman of SD Biosensor, Inc., and the CEO of SDB Investment, Cho has successfully founded SD Biosensor and Bionote to be a global diagnostic company for the human and veterinary field each. "For the past 2 years, humanity has suffered the unforeseen pandemic. Such illness can easily be eradicated with the cutting-edge technology utilizing A.I. (Artificial Intelligence)," said Cho. "Korea needs to actively support on the A.I. program to help flourish the bio industry." "I hope the contribution made today can be the stepping stone for the Korea's biotechnology industry." said Cho. Among the ₩25 billion donation, ₩20 billion will be dedicated to ‘Data Center Research Fund’ to build a GPU-based data center and support convergence research. Remaining ₩5 billion will be dedicated to the ‘Education and Research Environment Improvement Project Fund of the College of Veterinary Medicine’. Seoul National University has claimed that the donation will be cherished to support excellent researchers to induce innovation and growth.
The Korean Veterinary Association held 2nd National Veterinary Advisory Council (NVAC) at Bionote, Inc., on April 26th, 2022. The NVAC is an official advisory body within the Veterinary Society, providing advice to the government on the prevention of malignant livestock diseases such as FMD, ASF and major zoonotic diseases, while also serving to establish an official veterinary medical system. Key figures at NVAC 2022 includes: Chairman Yong-Ho Park (Seoul National University Veterinary College), ▲ Jong-Gu Kang (Biotoxtech), ▲ Jong-Kil Kang (Chunghyeon General Veterinary Hospital), ▲ Gon-Seop Kim (Gyeongsang National University Veterinary College), ▲ Woo-Joo Kim (Korea University Guro Hospital), ▲ Young-Soo Ryu (Konkuk University Veterinary College) , ▲Seungwon Seo (Boehringer Ingelheim Veterinary Medicine), ▲Sangcheol Shin (Solgent), ▲Chunggeun Yoon (Asia Veterinary Hospital), ▲Soodu Lee (Ministry of Food and Drug Safety), ▲Poongkyu Lee (Knowhere bio), ▲Youngsik Cho (Bionote). For this year's council meeting, Professor Kim Woo-Joo, Department of Infectious Diseases at the Korea University Guro Hospital, discussed the current status of the COVID-19 pandemic, development of vaccines, changes due to the emergence of mutants, and future prospects and countermeasures, under the theme of 'COVID-19 Pandemic: Current Status and Prospects'. Bionote is the No. 1 manufacturer for veterinary diagnostic reagents in Korea. For its post pandemic growth engine, Bionote will be focusing on expanding its business sector via molecular diagnostic analyzer Vcheck M, biochemistry analyzer Vcheck C, and bio-contents business.